Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications

We conducted a single-arm, phase 2 trial (German-Austrian Acute Myeloid Leukemia Study Group [AMLSG] 16-10) to evaluate midostaurin with intensive chemotherapy followed by allogeneic hematopoietic-cell transplantation (HCT) and a 1-year midosta urin maintenance therapy in adult patients with acute m...

Descripción completa

Detalles Bibliográficos
Autores principales: Döhner, Hartmut, Weber, Daniela, Krzykalla, Julia, Fiedler, Walter, Wulf, Gerald, Salih, Helmut, Lübbert, Michael, Kühn, Michael W. M., Schroeder, Thomas, Salwender, Hans, Götze, Katharina, Westermann, Jörg, Fransecky, Lars, Mayer, Karin, Hertenstein, Bernd, Ringhoffer, Mark, Tischler, Hans-Joachim, Machherndl-Spandl, Sigrid, Schrade, Anika, Paschka, Peter, Gaidzik, Verena I., Theis, Frauke, Thol, Felicitas, Heuser, Michael, Schlenk, Richard F., Bullinger, Lars, Saadati, Maral, Benner, Axel, Larson, Richard, Stone, Richard, Döhner, Konstanze, Ganser, Arnold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631686/
https://www.ncbi.nlm.nih.gov/pubmed/35486475
http://dx.doi.org/10.1182/bloodadvances.2022007223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631686/
https://www.ncbi.nlm.nih.gov/pubmed/35486475
http://dx.doi.org/10.1182/bloodadvances.2022007223

Ejemplares similares